Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

An Alternative Pathway Specific Flow Cytometric Assay to Detect Complement Activation in Atypical Hemolytic Uremic Syndrome (aHUS)

Jia Yu, Xuan Yuan, MD MSc, Kang Zhou, Daniel White, Samuel A. Merrill, MD PhD, Robert A. Brodsky, MD

Blood (2018) 132 (Supplement 1): 3748.

https://doi.org/10.1182/blood-2018-99-119445

Published: 2018

Journal Articles

TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer

Sophia Colombari Figueroa, BA, Bhumika J. Patel, MD, Shimoli Vipul Barot, MD, Teodora Kuzmanovic, BA, Aziz Nazha, Eric D. Hsi, MD, James R. Cook, MD PhD, Sudipto Mukherjee, MD PhD MPH, Aaron T. Gerds, MD MS, Mikkael A. Sekeres, MD MS, Matt Kalaycio, MD, Anjali S. Advani, MD, Jaroslaw P. Maciejewski, Hetty E. Carraway, MD MBA

Blood (2018) 132 (Supplement 1): 2270.

https://doi.org/10.1182/blood-2018-99-115562

Published: 2018

Journal Articles

Inhibition of Alternative Complement Pathway in Target Organs Represents a Novel and Effective Approach to Control Gvhd While Sparing GVL Effect

Hung D Nguyen, PhD, Ali Alawieh, MD PhDCandidate, David A Bastian, BS, Anusara Daenthanasanmak, PhD, Steven D Schutt, BS, Supinya Iamsawat, MSc, Yongxia Wu, PhD, Atkinson Carl, PhD, Stephen Tomlinson, PhD, Xue-Zhong Yu, PhD

Blood (2016) 128 (22): 807.

https://doi.org/10.1182/blood.V128.22.807.807

Published: 2016

Journal Articles

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Antonio M Risitano, MD PhD, Michael Storek, Leonardo Sahelijo, MD, Mittie Doyle, Yang Dai, Ilene Ceil Weitz, MD, Judith C.W. Marsh, MD, Modupe Elebute, MBChB, MD, Casey L O'Connell, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Giridharan Ramsingh, MD, Serena Marotta, MD, Andrzej Hellmann, Ante S. Lundberg, MD

Blood (2015) 126 (23): 2137.

https://doi.org/10.1182/blood.V126.23.2137.2137

Published: 2015

Journal Articles

Appropriateness of Thrombophilia Testing in Tertiary Care Centers in Edmonton

Alabdurubalnabi Zainab, MBBS, Salma Shivji, MD, Cynthia Wu, MD

Blood (2015) 126 (23): 4470.

https://doi.org/10.1182/blood.V126.23.4470.4470

Published: 2015

Journal Articles

Genotype Phenotype Correlation in Patients with aHUS and Abnormal Genetic Studies: A Single Centre Experience

Katerina Pavenski, MD FRCP, Jerome M. Teitel, MD, Gloria Lim, BSc, MSc, MD, Michelle Sholzberg, MD, Michael Kirschfink, Christoph Licht, MD FRCP(C), FASN

Blood (2014) 124 (21): 4186.

https://doi.org/10.1182/blood.V124.21.4186.4186

Published: 2014

Journal Articles

Detection of Paroxysmal Nocturnal Hemoglobinuria Clones in Patients with Idiopathic Venous Thromboembolism

Alejandro Lazo-Langner, MD MSc, Michael J. Kovacs, MD, Ben Hedley, PhD, Fatimah Al-Ani, MD, Michael Keeney, ART, FIMLS, FCSMLS(D), Martha L Louzada, BSc, MD MSc, Ian H. Chin-Yee, MD FRCPC

Blood (2014) 124 (21): 1532.

https://doi.org/10.1182/blood.V124.21.1532.1532

Published: 2014

Journal Articles

Increased Prevalence of Asthma Symptoms in Nigerian Children with Sickle Cell Disease Compared to Children without Sickle Cell Disease

Najibah Aliyu Galadanci, MBBS, Wayne Liang, MD, Muktar Aliyu, MD, DrPH, MPH, Binta Wudil Jibir, MBBS, MSc, Ibraheem Karaye, MBBS, Baba PD Inusa, MD, FRCPCH, Sten Vermund, MD, PhD, Michael R. DeBaun, MD, MPH

Blood (2012) 120 (21): 4760.

https://doi.org/10.1182/blood.V120.21.4760.4760

Published: 2012

Journal Articles

Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro

Antonio M. Risitano, MD, PhD, Patrizia Ricci, Caterina Pascariello, Maddalena Raia, Christoph Q Schmidt, Yingxue Li, Edimara S Reis, Michela Sica, PhD, Rosario Notaro, MD, Luigi Del Vecchio, MD, Fabrizio Pane, Daniel Ricklin, John D Lambris

Blood (2012) 120 (21): 370.

https://doi.org/10.1182/blood.V120.21.370.370

Published: 2012

Journal Articles

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization

Antonio M. Risitano, Rosario Notaro, Caterina Pascariello, Michela Sica, Luigi del Vecchio, Christopher J. Horvath, Masha Fridkis-Hareli, Carmine Selleri, Margaret A. Lindorfer, Ronald P. Taylor, Lucio Luzzatto, V. Michael Holers

Blood (2012) 119 (26): 6307–6316.

https://doi.org/10.1182/blood-2011-12-398792

Published: 2012

Includes: Supplemental data

Journal Articles

A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome

Nigel J. Francis, Bairbre McNicholas, Atif Awan, Mary Waldron, Donal Reddan, Denise Sadlier, David Kavanagh, Lisa Strain, Kevin J. Marchbank, Claire L. Harris, Timothy H. J. Goodship

Blood (2012) 119 (2): 591–601.

https://doi.org/10.1182/blood-2011-03-339903

Published: 2012

Includes: Supplemental data

Journal Articles

Family History of Venous Thromboembolism (VTE) and the Risk of VTE Recurrence in Patients with a First Unprovoked VTE: A Multicenter Prospective Cohort Study

Karine Gauthier, BSc, Elham Sabri, M.Sc., Susan R. Kahn, MD, MSc, Philip S Wells, David Anderson, Gregoire Le Gal, MD, PhD, Susan Solymoss, MD, Mark A. Crowther, MD, FRCPC, Arnaud Perrier, Richard H. White, MD, Michael J. Kovacs, MD, FRCPC, Marc Carrier, MD, MSc, Marc A. Rodger, MD, FRCPC

Blood (2011) 118 (21): 2299.

https://doi.org/10.1182/blood.V118.21.2299.2299

Published: 2011

Journal Articles

Family History of Venous Thromboembolism As a Risk Factor for Thrombosis in Multiple Myeloma Patients: A Population-Based Study,

Sigurdur Y Kristinsson, M.D., Ph.D., Lynn Goldin, PhD, Ingemar Turesson, MD, PhD, Magnus Bjorkholm, MD, PhD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 3987.

https://doi.org/10.1182/blood.V118.21.3987.3987

Published: 2011

Journal Articles

Retrospective Review of Erythropoietin Therapy Versus Supportive Care in Newborns with Hereditary Spherocytosis (HS): Difficulties Implementing Trial Results Into Clinical Practice

Jacqueline F. Morrison, Ellis J. Neufeld, MD, PhD, Rachael F. Grace, MD

Blood (2011) 118 (21): 2066.

https://doi.org/10.1182/blood.V118.21.2066.2066

Published: 2011

Journal Articles

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

Masha Fridkis-Hareli, Michael Storek, Istvan Mazsaroff, Antonio M. Risitano, Ante S. Lundberg, Christopher J. Horvath, V. Michael Holers

Blood (2011) 118 (17): 4705–4713.

https://doi.org/10.1182/blood-2011-06-359646

Published: 2011

Includes: Supplemental data

Journal Articles

Wheezing Is Associated with Increased Rates of Acute Chest Syndrome and Pain Episodes In Adults with Sickle Cell Disease

Robyn T. Cohen, MD, MPH, Anusha R. Madadi, MD, Morey A. Blinder, MD, Michael R. DeBaun, MD, MPH, Robert C. Strunk, MD, Joshua J. Field, MD

Blood (2010) 116 (21): 2647.

https://doi.org/10.1182/blood.V116.21.2647.2647

Published: 2010

Journal Articles

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Masha Fridkis-Hareli, PhD, Michael Storek, PhD, Antonio M. Risitano, MD, PhD, Ante S. Lundberg, MD, Christopher J Horvath, DVM, MS, DACVP, V. Michael Holers, MD

Blood (2010) 116 (21): 638.

https://doi.org/10.1182/blood.V116.21.638.638

Published: 2010

Journal Articles

TT30, a Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An in Vitro Model.

Antonio M. Risitano, MD, PhD, V. Michael Holers, Bruno Rotoli

Blood (2009) 114 (22): 158.

https://doi.org/10.1182/blood.V114.22.158.158

Published: 2009

Journal Articles

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

V. Michael Holers, Istvan Mazsaroff, PhD, Hillary Akana, Christopher G. Smith, J. Woodruff Emlen, MD, Russell C. Marians, PhD, Christopher J. Horvath, DVM

Blood (2009) 114 (22): 3021.

https://doi.org/10.1182/blood.V114.22.3021.3021

Published: 2009

Journal Articles

Findings of Thrombophilia Evaluation and Impact On Management in Asymptomatic Children with a Proximate Family History of Early Thromboembolism: An Institutional-Based Prospective Inceptional Cohort Study.

Meghan J. Calhoon, MS, Elizabeth Pounder, PA, Marilyn J. Manco-Johnson, MD, Neil A. Goldenberg, MD, PhD

Blood (2009) 114 (22): 1289.

https://doi.org/10.1182/blood.V114.22.1289.1289

Published: 2009

NARROW

An Alternative Pathway Specific Flow Cytometric Assay to Detect Complement Activation in Atypical Hemolytic Uremic Syndrome (aHUS)

TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer

Inhibition of Alternative Complement Pathway in Target Organs Represents a Novel and Effective Approach to Control Gvhd While Sparing GVL Effect

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Appropriateness of Thrombophilia Testing in Tertiary Care Centers in Edmonton

Genotype Phenotype Correlation in Patients with aHUS and Abnormal Genetic Studies: A Single Centre Experience

Detection of Paroxysmal Nocturnal Hemoglobinuria Clones in Patients with Idiopathic Venous Thromboembolism

Increased Prevalence of Asthma Symptoms in Nigerian Children with Sickle Cell Disease Compared to Children without Sickle Cell Disease

Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization

A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome

Family History of Venous Thromboembolism (VTE) and the Risk of VTE Recurrence in Patients with a First Unprovoked VTE: A Multicenter Prospective Cohort Study

Family History of Venous Thromboembolism As a Risk Factor for Thrombosis in Multiple Myeloma Patients: A Population-Based Study,

Retrospective Review of Erythropoietin Therapy Versus Supportive Care in Newborns with Hereditary Spherocytosis (HS): Difficulties Implementing Trial Results Into Clinical Practice

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

Wheezing Is Associated with Increased Rates of Acute Chest Syndrome and Pain Episodes In Adults with Sickle Cell Disease

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

TT30, a Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An in Vitro Model.

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

Findings of Thrombophilia Evaluation and Impact On Management in Asymptomatic Children with a Proximate Family History of Early Thromboembolism: An Institutional-Based Prospective Inceptional Cohort Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only